Skip to main content
    P

    Pyxis Oncology Inc (PYXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.44
    +0.03 (+2.13%)

    Market Cap: $188.98M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Pyxis Oncology Inc (PYXS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pyxis Oncology (PYXS) has a market cap of $188.98M and an enterprise value of $185.12M. It kept -852.17% of revenue as net income over the last 12 months. Revenue grew 463.09% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 2.04% below the market cap, as cash exceeds debt.

    Market Cap$188.98M
    Enterprise Value$185.12M
    Latest price (Nov 17, 2026)$1.44

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 30.50% in the quarter ended Sep 30, 2026 and grew 17.28% a year over 2 years.

    Shares Outstanding83.51M
    Shares Change (YoY)+33.49%
    Shares Change (QoQ)+30.50%
    Share Count Growth (2Y CAGR)+17.28%

    Valuation Ratios

    Sales and book value multiples are 11.8x and 2.9x. Its year-end P/S ranged from 4.9x to 41.8x from 2023 to 2025.

    P/S Ratio11.8x
    P/B Ratio2.9x

    Valuation history and multiples

    Price Statistics

    The stock is down 66.97% over 52 weeks and trades 35.43% below its 50-day average.

    Beta (1Y)1.21
    52-Week Change-66.97%
    1-Month Change-18.18%
    3-Month Change-57.27%
    6-Month Change-24.61%
    5-Year Change-86.43%
    Total Return (1Y)-66.97%
    Total Return (3Y CAGR)+0.23%
    Total Return (5Y CAGR)-35.75%
    Return vs SPY (1Y)-81.05%
    Max Drawdown (1Y)-80.15%
    Max Drawdown (3Y)-86.69%
    Sharpe Ratio (1Y)-0.90
    Correlation with SPY (1Y)0.13
    50-Day Average$2.23
    200-Day Average$2.16
    52-Week Range$1.03 to $5.55
    RSI (14 Days)31.1
    Average Volume (20 Days)779.54K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.96x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.96x
    Quick Ratio2.96x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -209.85% over the last 12 months, against a 5-year average of -75.19%.

    Return on Equity (ROE)-209.85%
    Return on Assets (ROA)-112.95%
    ROE (5Y Average)-75.19%
    ROA (5Y Average)-52.58%
    Asset Turnover0.11x

    Scores

    PYXS has an Altman Z-Score of -10.39, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-10.39
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $10.18M over the last 12 months.

    Revenue$10.18M
    Revenue Growth (YoY)+463.09%
    Gross Profit$7.79M
    Operating Income-$89.17M
    Pretax Income-$85.61M
    Net Income-$86.71M
    Reported EPS (TTM)-$1.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 53.82% of the $76.77M in total assets.

    Cash and Equivalents$3.86M
    Total Debt$0
    Net Cash$3.86M
    Net Cash Per Share$0.05
    Working Capital$39.19M
    Shareholder Equity$41.32M
    Book Value Per Share$0.49
    Total Assets$76.77M
    Total Liabilities$35.45M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$70.93M
    FCF Per Share-$0.59
    Depreciation and Amortization$5.10M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -876.34%.

    Gross Margin76.53%
    Operating Margin-876.34%
    Pretax Margin-841.33%
    Net Margin-852.17%

    Growth

    Book Value Per Share Growth (2Y CAGR)-44.68%
    Tangible Book Per Share Growth (2Y CAGR)-38.41%

    Revenue and profit by year

    Dividends and Yields

    PYXS does not pay a dividend.

    Buyback Yield-40.29%
    Shareholder Yield-40.29%

    Peer Position

    Against 6 similar companies, PYXS has the 3rd highest P/S.

    P/S Ratio11.8x vs 4.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+463.09% vs -31.10% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -99.86% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)-99.86%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PYXS

    What is PYXS's market cap?

    Pyxis Oncology has a market cap of $188.98M. Its enterprise value, which adds debt and subtracts cash, is $185.12M.

    How many shares of PYXS are outstanding?

    Pyxis Oncology has 83.51M shares outstanding. The count is up 33.49% from a year earlier.

    Does PYXS pay a dividend?

    No. Pyxis Oncology does not pay a dividend.

    How much debt does PYXS have?

    Pyxis Oncology has $0 of total debt and $3.86M of cash and equivalents, a net cash position of $3.86M.